Literature DB >> 26943726

Genotyping of Fusarium Isolates from Onychomycoses in Colombia: Detection of Two New Species Within the Fusarium solani Species Complex and In Vitro Antifungal Susceptibility Testing.

Marcela Guevara-Suarez1,2, José Francisco Cano-Lira2, María Caridad Cepero de García1, Leticia Sopo3, Catalina De Bedout4, Luz Elena Cano5, Ana María García6, Adriana Motta7,8, Adolfo Amézquita9, Martha Cárdenas1, Ana Espinel-Ingroff10, Josep Guarro2, Silvia Restrepo1, Adriana Celis11.   

Abstract

Fusariosis have been increasing in Colombia in recent years, but its epidemiology is poorly known. We have morphologically and molecularly characterized 89 isolates of Fusarium obtained between 2010 and 2012 in the cities of Bogotá and Medellín. Using a multi-locus sequence analysis of rDNA internal transcribed spacer, a fragment of the translation elongation factor 1-alpha (Tef-1α) and of the RNA-dependent polymerase subunit II (Rpb2) genes, we identified the phylogenetic species and circulating haplotypes. Since most of the isolates studied were from onychomycoses (nearly 90 %), we carried out an epidemiological study to determine the risk factors associated with such infections. Five phylogenetic species of the Fusarium solani species complex (FSSC), i.e., F. falciforme, F. keratoplasticum, F. lichenicola, F. petroliphilum, and FSSC 6 as well as two of the Fusarium oxysporum species complex (FOSC), i.e., FOSC 3 and FOSC 4, were identified. The most prevalent species were FOSC 3 (38.2%) followed by F. keratoplasticum (33.7%). In addition, our isolates were distributed into 23 haplotypes (14 into FOSC and nine into FSSC). Two of the FSSC phylogenetic species and two haplotypes of FSSC were not described before. Our results demonstrate that recipients of pedicure treatments have a lower probability of acquiring onychomycosis than those not receiving such treatments. The antifungal susceptibility of all the isolates to five clinically available agents showed that amphotericin B was the most active drug, while the azoles exhibited lower in vitro activity.

Entities:  

Keywords:  Haplotypes; Pedicure; Phylogenetic species; Susceptibility

Mesh:

Substances:

Year:  2016        PMID: 26943726     DOI: 10.1007/s11046-016-9983-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  49 in total

1.  Use of the Diversi Lab System for species and strain differentiation of Fusarium species isolates.

Authors:  M Healy; K Reece; D Walton; J Huong; S Frye; I I Raad; D P Kontoyiannis
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

2.  Mixed infection caused by two species of Fusarium in a human immunodeficiency virus-positive patient.

Authors:  J Guarro; M Nucci; T Akiti; J Gené
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

3.  Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.

Authors:  Abdullah M S Al-Hatmi; Anne D van Diepeningen; Ilse Curfs-Breuker; G Sybren de Hoog; Jacques F Meis
Journal:  J Antimicrob Chemother       Date:  2014-12-23       Impact factor: 5.790

4.  Voriconazole treatment for less-common, emerging, or refractory fungal infections.

Authors:  John R Perfect; Kieren A Marr; Thomas J Walsh; Richard N Greenberg; Bertrand DuPont; Juliàn de la Torre-Cisneros; Gudrun Just-Nübling; Haran T Schlamm; Irja Lutsar; Ana Espinel-Ingroff; Elizabeth Johnson
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

5.  Onychomycosis in Cali, Colombia.

Authors:  Maria Inés Alvarez; Luz Angela González; Luz Angela Castro
Journal:  Mycopathologia       Date:  2004-08       Impact factor: 2.574

6.  Clinical and epidemiological aspects of infections caused by fusarium species: a collaborative study from Israel.

Authors:  Ran Nir-Paz; Jacob Strahilevitz; Mervyn Shapiro; Nathan Keller; Anna Goldschmied-Reouven; Oded Yarden; Colin Block; Itzhack Polacheck
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

7.  [Onychomycosis by common non-dermatophyte moulds].

Authors:  Martha Lucía Escobar; Jaime Carmona-Fonseca
Journal:  Rev Iberoam Micol       Date:  2003-03       Impact factor: 1.044

8.  Phylogenetic diversity and microsphere array-based genotyping of human pathogenic Fusaria, including isolates from the multistate contact lens-associated U.S. keratitis outbreaks of 2005 and 2006.

Authors:  Kerry O'Donnell; Brice A J Sarver; Mary Brandt; Douglas C Chang; Judith Noble-Wang; Benjamin J Park; Deanna A Sutton; Lynette Benjamin; Mark Lindsley; Arvind Padhye; David M Geiser; Todd J Ward
Journal:  J Clin Microbiol       Date:  2007-05-16       Impact factor: 5.948

Review 9.  Fusarium infections in immunocompromised patients.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

10.  Molecular phylogenetic diversity of dermatologic and other human pathogenic fusarial isolates from hospitals in northern and central Italy.

Authors:  Quirico Migheli; Virgilio Balmas; Henry Harak; Silvana Sanna; Barbara Scherm; Takayuki Aoki; Kerry O'Donnell
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948

View more
  12 in total

1.  Development of a polymerase chain reaction-restriction fragment length polymorphism method for identification of the Fusarium genus using the transcription elongation factor-1α gene.

Authors:  Majid Zarrin; Farzaneh Ganj; Sama Faramarzi
Journal:  Biomed Rep       Date:  2016-10-18

2.  The Curious Case of "Case Report" of Infections Caused by Human and Animal Fungal Pathogens: An Educational Tool, an Online Archive, or a Format in Need of Retooling.

Authors:  Jean-Philippe Bouchara; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2018-12       Impact factor: 2.574

3.  Demonstration of Adventitious Sporulation in Fusarium Petroliphilum Onychomycosis.

Authors:  Ziauddin Khan; Suhail Ahmad; Wadha Alfouzan; Leena Joseph; Soumya Varghese
Journal:  Mycopathologia       Date:  2019-02-08       Impact factor: 2.574

4.  Challenges in Fusarium, a Trans-Kingdom Pathogen.

Authors:  Anne D van Diepeningen; G Sybren de Hoog
Journal:  Mycopathologia       Date:  2016-03-10       Impact factor: 2.574

5.  Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015.

Authors:  Abdullah Ms Al-Hatmi; Ferry Hagen; Steph Bj Menken; Jacques F Meis; G Sybren de Hoog
Journal:  Emerg Microbes Infect       Date:  2016-12-07       Impact factor: 7.163

6.  Cutaneous Fusariosis in a Patient with Job's (Hyper-IgE) Syndrome.

Authors:  Ahmed M Altibi; Radhika Sheth; Ayman Battisha; Vivek Kak
Journal:  Case Rep Infect Dis       Date:  2020-06-15

7.  Removing chaos from confusion: assigning names to common human and animal pathogens in Neocosmospora.

Authors:  M Sandoval-Denis; P W Crous
Journal:  Persoonia       Date:  2018-04-04       Impact factor: 11.051

8.  Biofilm Formation and Resistance to Fungicides in Clinically Relevant Members of the Fungal Genus Fusarium.

Authors:  Hafize Sav; Haleh Rafati; Yasemin Öz; Burcu Dalyan-Cilo; Beyza Ener; Faezeh Mohammadi; Macit Ilkit; Anne D van Diepeningen; Seyedmojtaba Seyedmousavi
Journal:  J Fungi (Basel)       Date:  2018-01-23

9.  Airborne transmission of invasive fusariosis in patients with hematologic malignancies.

Authors:  Maria Luiza Moretti; Ariane Fidelis Busso-Lopes; Cibele Aparecida Tararam; Renato Moraes; Yasunori Muraosa; Yuzuru Mikami; Tohru Gonoi; Hideaki Taguchi; Luzia Lyra; Franqueline Reichert-Lima; Plínio Trabasso; Gerrit Sybren de Hoog; Abdullah Mohammed Said Al-Hatmi; Angelica Zaninelli Schreiber; Katsuhiko Kamei
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

10.  A 23 bp cyp51A Promoter Deletion Associated With Voriconazole Resistance in Clinical and Environmental Isolates of Neocosmospora keratoplastica.

Authors:  Jasper Elvin James; Erwin Lamping; Jacinta Santhanam; Trudy Jane Milne; Mohd Fuat Abd Razak; Latiffah Zakaria; Richard David Cannon
Journal:  Front Microbiol       Date:  2020-03-31       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.